<code id='17A391CFB6'></code><style id='17A391CFB6'></style>
    • <acronym id='17A391CFB6'></acronym>
      <center id='17A391CFB6'><center id='17A391CFB6'><tfoot id='17A391CFB6'></tfoot></center><abbr id='17A391CFB6'><dir id='17A391CFB6'><tfoot id='17A391CFB6'></tfoot><noframes id='17A391CFB6'>

    • <optgroup id='17A391CFB6'><strike id='17A391CFB6'><sup id='17A391CFB6'></sup></strike><code id='17A391CFB6'></code></optgroup>
        1. <b id='17A391CFB6'><label id='17A391CFB6'><select id='17A391CFB6'><dt id='17A391CFB6'><span id='17A391CFB6'></span></dt></select></label></b><u id='17A391CFB6'></u>
          <i id='17A391CFB6'><strike id='17A391CFB6'><tt id='17A391CFB6'><pre id='17A391CFB6'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:hotspot    Page View:33944
          Buildings like hospitals and banks on a web with people operating laptops and phones — health tech coverage from STAT
          Adobe

          For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

          But just because it was simple didn’t mean it was going to work.

          advertisement

          The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated. Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. Even after hitting roadblock after roadblock, the company stuck to its original plan and ended up vaporizing over $400 million in investment before finally throwing in the towel.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Biotech venture capitalists face new demands from investors
          Biotech venture capitalists face new demands from investors

          AdobeOverthelastyearortwo,somethingcurioushasstartedoccurringintheconferenceroomsandprivateZoommeeti

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          New details revealed about Purdue's marketing of OxyContin

          MassachusettsAttorneyGeneralMauraHealeyJessicaRinaldi/TheBostonGlobeWhenPurduePharmastartedsellingit